A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment von El-Khoueiry, Anthony B., Tchekmedyian, Nishan, Sanborn, Rachel E., Peguero, Julio Antonio, Pulver, Kerry, Dembla, Vikas, Thomas, Jacob Stephen, Chiang, Gary Gene, Densel, Mark, Sankar, Neil, Worland, Stephen Theodore, Gleich, Lyon L., Sikorski, Robert S.

Volltext

A phase II, open label, randomized, noncomparative study of eFT508 (tomivosertib) alone or in combination with avelumab in subjects with relapsed/refractory microsatellite stable c... von Hubbard, Joleen Marie, Patel, Manish R., Bekaii-Saab, Tanios S., Falchook, Gerald Steven, Freilich, Bradley L., Dasari, Arvind, Knisely, Benjamin T, Anderson, Marlisa, Chiang, Gary Gene, Webster, Kevin R, Sperry, Sam, Barton, Jeremy, Bendell, Johanna C.

Volltext

A phase 1 dose escalation study of eFT508, an inhibitor of mitogen-activated protein kinase-interacting serine/threonine kinase-1 (MNK-1) and MNK-2 in patients with advanced solid... von Falchook, Gerald Steven, Infante, Jeffrey R., Meric-Bernstam, Funda, Miller, Langdon L., Morison, Karen, Vallner, Debra, Sperry, Sam, Goel, Vikas, Chiang, Gary Gene, Webster, Kevin, Barton, Jeremy, Patel, Manish R.

Volltext

Genetic effects on gene expression across human tissues von Battle, Alexis, Brown, Christopher D, Engelhardt, Barbara E, Montgomery, Stephen B

Volltext